COMPOUND PROFILE / COMBINATIONS
Ipamorelin + CJC-1295 DAC.
Research draftThis entry combines ipamorelin with CJC-1295 DAC.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Identity and evidence review notes
Component references are background only. No directly matched controlled combination result was established in this pass.
Overview
This entry combines ipamorelin with CJC-1295 DAC.
Mechanism
It pairs ghrelin-receptor activity with prolonged GHRH signalling.
Human research
Component hormone studies do not establish exact-combination recovery, muscle or longevity benefit.
Preclinical & other research
Separate pharmacology provides a rationale, not proven synergy.
Safety & unknowns
Prolonged GH-axis effects, glucose responses and long-term combined safety are uncertain.
Regulatory status
No exact-combination approval was established; keep separate from the No-DAC combination.
Reported use & evidence
The supplied Ipamorelin + CJC-1295 DAC profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.